Drugs · acquisition-cost intelligence
Spritam
levetiracetam· ingredient levetiracetamOther antiepileptics· LEVETIRACETAM 1000 mg/1; LEVETIRACETAM 250 mg/1; LEVETIRACETAM 500 mg/1; LEVETIRACETAM 750 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$10.27
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 4 weeks.
2025-08-202026-02-18
Same-ingredient options by acquisition cost
Other levetiracetam products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Levetiracetam | $0.03031 | −$10.24 |
| Roweepra | $0.07804 | −$10.19 |
| levetiracetam | $0.09735 | −$10.17 |
| Keppra XR | $0.24408 | −$10.03 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.